Dynavax Technologies Corp
NASDAQ:DVAX
Dynavax Technologies Corp
NASDAQ:DVAX
Price:
11.04 USD
0.36%
Market Closed
Updated:
May 16, 2024
Section:
Relative Value
The Relative Value of one
DVAX
stock under the Base Case scenario is
10.21
USD.
Compared to the current market price of 11.04 USD,
Dynavax Technologies Corp
is
Overvalued by 8%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DVAX
Relative Value
Base Case
10.21
USD
Overvaluation 8%
Valuation Multiples
Multiples Across Competitors
DVAX Competitors Multiples
Dynavax Technologies Corp Competitors
Dynavax Technologies Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Dynavax Technologies Corp
NASDAQ:DVAX
|
1.4B USD | 6.1 | 157.1 | -56.8 | -44.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.1B USD | 5.3 | 60 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 5.8 | 45.5 | 19.1 | 31.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.4 | 31.1 | 25.2 | 26.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.2 | 27.9 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
136.7B AUD | 6.5 | 37.1 | 22.4 | 27.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.7B USD | 3 | 172.9 | 7 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.3B USD | 9.6 | -8.3 | -9.1 | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.2B USD | 3.5 | 29.3 | 14.9 | 18.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
